By probing the molecular basis of proteasome inhibitor resistance in cancer cells, a Broad-led team finds new vulnerability — and compounds that exploit it.
Long thought to be genetically stable and identical, cancer cell lines harbor significant levels of genetic variation, which may help explain why it can be hard to reproduce findings in cell line-based research.